Introduction Several trials have demonstrated that angiotensin converting enzyme inhibitors (ACEIs) decrease cardiovascular (CV) mortality rates in patients with heart failure; however, the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) trials failed to show significant similar preventive effects in normal ejection fraction patients. We evaluated the baseline coronary artery calcium (CAC) score as a predictor of the effects of ACEIs/ angiotensin receptor blockers (ARBs) on outcomes among normal ejection fraction participants.
Methodology Of 6814 MultiEthnic Study for Atherosclerosis population participants (after exclusion of the patients temporarily using ACEIs and/or ARBs during follow-up), we evaluated 2906 participants who never used ACEIs/ARBs and 368 (8.7%) participants who constantly used them during all baseline and follow-up examinations. In the population studied, 53.9% were men, aged 60.8 ± 10.0 years, who had no apparent clinical CV disease. We compared CV event rates and multivariable-adjusted hazard ratios after stratifying by ACEI/ARB use and stratifying CAC scores by category (0, 1-399, and ≥ 400).
Results
The event rates varied from 1.8 to 41.2/1000 person years among the CAC groups. Among the participants with a 1-399 CAC score, ACEI/ARB users had significantly lower event rates than nonusers (4.9 vs. 8.2, respectively). Hazard ratio in the adjusted model was 3.1 (95% confidence interval 1. 14-8.78 , P < 0.05). There was no significant event rate difference between ACEI/ARB users and nonusers among other CAC groups.
Conclusion
The use of ACEIs/ARBs was associated with significantly fewer CV events in asymptomatic participants with low to intermediate CAC scores. Thus, better risk stratification in asymptomatic individuals (such as using CAC scores) may assist in proper selection of patients for further CV risk reduction strategies. Coron Artery Dis 26:678-685 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
The renin-angiotensin-aldosterone system (RAAS) plays an important role in blood pressure (BP), cardiovascular disease (CVD), and renal function. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are medications that were developed to attenuate the effect of RAAS. Currently, these medications are widely utilized for the treatment of congestive heart failure, myocardial infarction, and hypertension, as well as for the prevention of macrovascular and microvascular complications of diabetes. In addition, they have been shown to slow the progression of chronic kidney disease to end-stage renal disease. In 2009, ACEIs were the fourth most utilized drug class in the USA, and they were prescribed 162.8 million times by US physicians [1] .
Both ACEIs and ARBs are medications that have proven efficacy in lowing mortality and morbidity rates [2] . Among patients with congestive heart failure, the Studies of Left Ventricular Dysfunction (SOLVD) trial showed that enalapril significantly improved survival and reduced further hospitalization rates [2] . Moreover, in the Survival And Ventricular Enlargement trial, captopril was able to decrease the risk for recurrent myocardial infarction [3] . In the Heart Outcomes Prevention Evaluation study, among high-risk patients, ramipril lowered the risk for atherosclerotic events including stroke, myocardial infarction, and cardiovascular death. The benefits were independent of the effect of ramipril on BP and cardiac systolic function [4] . However, in the Captopril Prevention Project study of 10 985 patients, there was no difference in cardiovascular morbidity and mortality rates. In this study, Captopril failed to show any advantage over conventional therapy in preventing cardiovascular morbidity and mortality [5] . The discrepancies in the effect of these medications on the rate of cardiovascular events across different trials suggest that we need to find better criteria to predict who may benefit from these medications. Evaluation of the Framingham risk score (FRS) has been a poor predictor of who will benefit from ACE inhibition. In this study, we sought to examine whether the coronary artery calcium (CAC) score can determine which individuals would benefit from the effects of ACEIs or ARBs (in the form of fewer cardiovascular events). There are no guidelines for instituting ACEI or ARB therapy based on the CAC score or FRS. The goal of this study was to identify a subgroup of primary prevention patients who may benefit from ACE inhibition for reducing CV risk, not reducing complications of diabetes mellitus (albuminuria) or hypertension (left-ventricular hypertrophy).
Methodology Population characteristics
The MultiEthnic Study of Atherosclerosis (MESA) is a prospective study intended to evaluate development and progression of subclinical CVD in clinically asymptomatic individuals among different ethnic groups. In this study, participants from four different ethnicities were enrolled (White, African American, Hispanic, and Asian, predominantly of Chinese descent) at six Field Centers (Forsyth County, North Carolina; Northern Manhattan and the Bronx, New York; Baltimore City and Baltimore County, Maryland; St. Paul, Minnesota; Chicago and the village of Maywood, Illinois; and Los Angeles County, California). All participants underwent extensive evaluation at baseline, including clinical history taking, physical examination, and many laboratory tests. The MESA protocol, including information about the populations and the recruitment method, the inclusion and exclusion criteria, the investigators' contact information, and other detailed information, is available at http://www. mesa-nhlbi.org. Of the 6814 MESA participants, we enrolled all 2906 participants who had either never used ACEIs or ARBs (n = 2457, 84.5%) or were taking any of these medications (n = 449, 15.5%) during the baseline and follow-up years. Participants who were taking these medications intermittently were excluded. They were followed up for an average of 8.0 1.7 years (range 0.02-10.9 years). Our selected population, 49.0% of which was male and had an average age of 60.1 9.7 years (range 45-84 years), had no apparent clinical CVD at the baseline ( Table 1 ). All participants underwent a noncontrast-enhanced cardiac computerized tomography (cardiac CT) and were evaluated for CAC score. According to the participants' CAC score and selfreported utilization of ACEIs and ARBs, they were categorized into six different groups: zero CAC with ACEIs/ARBs (n = 163), zero CAC without ACEIs/ARBs (n = 1440), intermediate CAC scores with ACEIs/ ARBs (n = 203), intermediate CAC scores without ACEI/ARBs (n = 865), higher CAC scores (≥400) with ACEIs/ARBs (n = 83), and high CAC scores without ACEIs/ARBs (n = 152). Moreover, to examine the superiority of the CAC score as compared with the FRS score, we divided participants into six groups on the basis of FRS groups (low, intermediate, and high) and ACEI/ ARB use: low FRS with ACEIs/ARBs (n = 92), low FRS without ACEIs/ARBs (n = 1531), intermediate FRS with ACEIs/ARBs (n = 126), intermediate FRS without ACEIs/ARBs (n = 575), high FRS with ACEIs/ARBs (n = 231), and high FRS without ACEIs/ARBs (n = 351). Among all participants, 55.2% (n = 1603) had zero CAC score and 8.1% (n = 235) had a CAC score of more than 400 (Tables 2 and 3 ).
Data collection
All participants signed informed consent forms and were evaluated at baseline examination between July 2000 and July 2002. In addition, they were evaluated at four followup examinations as follows: a second examination between July 2002 and January 2004, a third examination between January 2004 and July 2005, a fourth examination between July 2005 and July 2007, and a fifth examination between April 2010 and April 2012. The components of each examination have been described in Table 3 . Data on demographics, medical conditions, family history of CVD, and current use of prescription and nonprescription medication were collected through questionnaires. During the examination, height, weight, and waist and hip circumferences were measured. Resting BP was measured three times in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, Florida, USA).
Coronary artery calcium score
Cardiac CT scans were obtained either using a cardiacgated electron-beam CT scanner (the Chicago, Los Angeles, and New York field centers; Imatron C-150; Imatron, San Francisco, California, USA) or through prospective electrocardiogram-triggered scan acquisition at 50% of the R-R interval with a multidetector CT, acquiring a block of four 2.5-mm slices for each cardiac cycle in a sequential or axial scan mode (the Baltimore, Forsyth County, and St Paul field centers; Lightspeed; General Electric Medical Systems, Waukesha, Wisconsin, USA; or Volume Zoom; Siemens, Erlanger, Germany). All participants were scanned over phantoms with known physical density. CAC scores were evaluated centrally at the Los Angeles Biomedical Research Center at Harbor-UCLA in Torrance, California, USA.
Cardiovascular events
All events were described as CVD events including myocardial infarction, resuscitated cardiac arrest, definite and probable angina (only if followed by revascularization), stroke, stroke death, coronary heart disease death, other atherosclerotic death, as well as all other cardiovascular deaths. Silent myocardial infarctions were identified using criteria applied to the follow-up ECG. Resuscitated cardiac arrest and other CVD endpoints were identified from medical records. To classify CVD events occurring during follow-up, information has been collected from death certificates, hospital medical records, autopsy reports, and interviews with the participants, and, for those who died out of the hospital, data were collected through interviews or questionnaires administered to the physicians, relatives, or friends of the patients.
Statistical analysis methods
To address the objective of the study, a number of statistical analyses were carried out. Participants were classified into groups that used and did not use ACEIs and/or ACEI/ARB use. We assessed the cardiovascular event rate per 1000 person-years of both ACEI/ARB users and nonusers, stratified by CAC score or FRS. In addition to the univariate Cox regression analysis, unadjusted and adjusted multivariate Cox proportional hazard models were used to calculate hazard ratios (HRs) for the relationship between ACEI/ARB usage stratified by CAC score/FRS and all cardiovascular events. We considered the user group as the reference for these analyses. Further adjustments were made in two steps. Covariates were entered into the model on the basis of their potential roles as confounders. The covariates used in the first step were demographics, smoking, diabetes, hypertension, hyperlipidemia, and family history of premature CVD. In the second step, aspirin and statin usage were added to the model. Kaplan-Meier plots were presented for all cardiovascular events over ACEI and/or ARB and CAC score/FRS groups. All statistical analysis were carried out using SAS software, version 9.3 (SAS Institute Inc., Cary, North Carolina, USA), and statistical significance levels of all the analyses were set at a P-value of 0.05 (two-sided).
Results
In total, 2906 participants (52.6% female) with a mean age of 60.1 years (range 45-84 years) were followed up for an average of 8.0 1.7 years (range 0.02-10.9 years In total, 248 (8.5%) CVD events were recorded. Event rates were greater among the groups with a greater CAC score and/or FRS (see Fig. 1 , Tables 4 and 5 ). Moreover, ACEI/ARB users had a significantly greater rate of CVD events than the nonuser group (17.1 and 7.0%, respectively; Table 2 ).
Among the patients with normal CAC scores, unadjusted
Cox regression analysis showed that, compared with users, nonusers had a significantly lower risk for events [HR = 0.37, 95% confidence interval (CI): 0.18-0.78, P < 0.05]. However, when they were adjusted by major CVD risk factors (adjusted model 1) or major CVD risk factors plus statin and aspirin use (adjusted model 2), no significant difference persisted. CACs, coronary artery calcium score; FRS, Framingham risk score. In contrast, among the patients with an intermediate CAC score, both adjusted models showed a significantly greater event rate among those who did not use ACEIs/ ARBs. In this group, the ACEI/ARB nonusers showed a significantly higher HR for all CVD events (HR = 1.6, 95% CI: 1.0-2.6, P < 0.05 in model one and HR = 3. 3, 95% CI: 1.1-10.4, P < 0.05 in model two; Figs 2-4) .
Among the patients with a high CAC score, despite significant differences in unadjusted models, adjusted models failed to show any significant difference in terms of the use of ACEIs/ARBs (Table 6) .
In contrast to classification on the basis of the CAC score, no significant difference was observed between groups when they were classified on the basis of FRS (Table 7 ).
Discussion
RAAS inhibitors reduce prothrombotic activity, modify anti-inflammatory mediators, and reduce plaque rupture.
In addition, ACEIs have been shown to improve coronary artery endothelial function. There are many studies demonstrating a significant improvement in both survival and quality of life with ACEI and/or ARB use among patients with heart failure [6] . However, appropriate Distribution of all cardiovascular events on the basis of the Framingham risk score (FRS) and the presence of coronary artery calcification. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAC, coronary artery calcium; FRS, Framingham risk score.
selection of patients for treatment with ACEIs and/or ARBs is challenging. Currently many patients without heart failure are using these medications. Despite data that indicate that ACEIs may decrease event rates in patients with hypertension, it is not clear which patients will benefit. Furthermore, some trials were not able to show any overall benefit [7] . The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial, which enrolled 8290 participants with normal or near-normal left-ventricular ejection fraction, reported that cardiovascular event rates did not differ when they were adjusted for major cardiovascular risk factors.
In our study, patients who received ACEIs and/or ARBs throughout follow-up had a greater average of both FRS and CAC scores. Therefore, generally, patients who took ACEIs and/or ARBs had greater risk and event rates, most likely because of the underlying indications for ACEI and ARB use (Figs 1-3) . Similarly, when we divided patients on the basis of their FRS, the ACEI/ ARB nonuser group had fewer events than ACEI or ARB users, but this effect was attenuated by the presence of diabetes and other non-FRS risk factors.
When we classified our population on the basis CAC scores, even after adjustment for risk factors or risk factors plus statin and aspirin use, patients with intermediate CAC scores were found to have fewer events if they were on ACEIs/ARBs. In contrast, in the groups with a CAC score of 0 or CAC scores higher than 400, our results showed that there was no significant difference between participants who took ACEIs/ARBs and those who did not. It has been demonstrated that patients with a CAC score of 0 have very low CV event rates. Therefore, it is difficult to show benefit from further risk reduction. With regard CAC scores greater than 400, it is possible that these participants, although at high cardiovascular risk, have more established atherosclerosis, which may be less amenable to different therapies [8] [9] [10] . Some clinical and biomechanical studies have revealed that plaque composition has an important role in acute clinical events. It is possible that more calcified lesions are less vulnerable to rupture and spotty calcification, and mixed plaques are more likely to be associated with future CV events [11 -13] . Interestingly, our study shows that, in contrast to the CAC score, FRS did not help in stratification of patients who would benefit from ACEIs/ARBs. No FRS was associated with lower cardiovascular event rates between ACEI/ARB users and nonusers (Table 7) .
Limitations
We excluded participants who used ACEIs and/or ARBs temporarily, as the follow-up reflected both time on and time off these medications. We included all participants who were consistently taking ACEIs/ARBs from the baseline visit until the end of follow-up. Of course, a randomized trial in patients with an intermediate CAC score would be most definitive, but this is unlikely to be performed.
Conclusion
Participants with intermediate CAC scores (defined as scores between 1 and 399), who were on ACEIs and/or ARBs, experienced fewer cardiovascular events in the future compared with those not administering these therapies. In addition, the FRS could not define patients who may or may not have benefitted from ACEIs/ARBs in this observational study. These CAC results can be obtained on a dedicated heart scan or on thoracic imaging for lung cancer screening [14] . Although a randomized prospective trial would be confirmatory, this study adds critical information that the cardioprotective effects of agents may be dependent on baseline CV risk, and the prognostic information received from CAC scores may help determine optimal medical regimens.
